Page 132 - 《中国药房》2024年3期

Hum Mol Genet，2019，28（3）：448-458. oxidants （Basel），2022，11（11）：2122.
[16] CATALANO M，RAMELLO M，CONCA R，et al. Risk [27] SUN H，GUO X，WANG Z T，et al. Alphalipoic acid pre‐
factors for nab-paclitaxel and gemcitabine-induced vents oxidative stress and peripheral neuropathy in nab-
peripheral neuropathy in patients with pancreatic cancer paclitaxel-treated rats through the Nrf2 signalling pathway
[J]. Oncology，2022，100（7）：384-391. [J]. Oxid Med Cell Longev，2019，2019：3142732.
[17] GUO Q，ZHANG H N，LI X，et al. Risk factors for [28] MIRONOV S L，IVANNIKOV M V，JOHANSSON M.
chemotherapy-induced peripheral neuropathy caused by [Ca ]i signaling between mitochondria and endoplasmic
2+
nanoparticle albumin-bound paclitaxel in advanced breast reticulum in neurons is regulated by microtubules. From
cancer[J]. Biomed Res Int，2022，2022：9430952. mitochondrial permeability transition pore to Ca -induced
2+
[18] BIGANZOLI L，CINIERI S，BERARDI R，et al. Ca release[J]. J Biol Chem，2005，280（1）：715-721.
2+
EFFECT：a randomized phase Ⅱ study of efficacy and im‐ [29] CHEN Y，LU R，WANG Y，et al. Shaoyao gancao decoc‐
pact on function of two doses of nab-paclitaxel as first- tion ameliorates paclitaxel-induced peripheral neuropathy
line treatment in older women with advanced breast cancer via suppressing TRPV1 and TLR4 signaling expression in
[J]. Breast Cancer Res，2020，22（1）：83. rats[J]. Drug Des Devel Ther，2022，16：2067-2081.
[19] HIRAMOTO S，ASANO H，MIYAMOTO T，et al. Risk [30] ADAMEK P，HELES M，BHATTACHARYYA A，et al.
factors and pharmacotherapy for chemotherapy-induced Dual PI3Kδ/γ inhibitor duvelisib prevents development of
peripheral neuropathy in paclitaxel-treated female cancer neuropathic pain in model of paclitaxel-induced peripheral
survivors：a retrospective study in Japan[J]. PLoS One， neuropathy[J]. J Neurosci，2022，42（9）：1864-1881.
2021，16（12）：e0261473. [31] KHANNA R，YU J，YANG X F，et al. Targeting the
[20] RIVERA E，CIANFROCCA M. Overview of neuropathy CaVα -CaVβ interaction yields an antagonist of the N-
associated with taxanes for the treatment of metastatic type CaV2.2 channel with broad antinociceptive efficacy[J].
breast cancer[J]. Cancer Chemother Pharmacol，2015，75 Pain，2019，160（7）：1644-1661.
（4）：659-670. [32] FLATTERS S J L，DOUGHERTY P M，COLVIN L A.
[21] SCHNEIDER B P，ZHAO F M，WANG M L，et al. Neu‐ Clinical and preclinical perspectives on Chemotherapy-
ropathy is not associated with clinical outcomes in pa‐ Induced Peripheral Neuropathy （CIPN）：a narrative re‐
tients receiving adjuvant taxane-containing therapy for view[J]. Br J Anaesth，2017，119（4）：737-749.
operable breast cancer[J]. J Clin Oncol，2012，30（25）： [33] BRANDOLINI L，CASTELLI V，ARAMINI A，et al.
3051-3057. DF2726A，a new IL-8 signalling inhibitor，is able to coun‐
[22] HIRSH V，KO A，PILOT R，et al. Weekly nab-paclitaxel teract chemotherapy-induced neuropathic pain[J]. Sci
in combination with carboplatin as first-line therapy in pa‐ Rep，2019，9（1）：11729.
tients with advanced non-small-cell lung cancer：analysis [34] KARMAKAR V，MOHAMMAD F S，BAEESA S S，et
of safety and efficacy in patients with diabetes[J]. Clin al. Effect of cliothosa aurivilli on paclitaxel-induced pe‐
Lung Cancer，2016，17（5）：367-374. ripheral neuropathy in experimental animals[J]. Mol Neu‐
[23] BAE E H，GREENWALD M K，SCHWARTZ A G. robiol，2022，59（4）：2232-2245.
Chemotherapy-induced peripheral neuropathy：mecha‐ [35] PETROSINO S，SCHIANO MORIELLO A. Palmitoyle‐
nisms and therapeutic avenues[J]. Neurotherapeutics， thanolamide：a nutritional approach to keep neuroinflam‐
2021，18（4）：2384-2396. mation within physiological boundaries：a systematic
[24] MORI K，KAWASHIRI T，MINE K，et al. Inhibitory ef‐ review[J]. Int J Mol Sci，2020，21（24）：9526.
fect of α1 receptor antagonists on paclitaxel-induced pe‐ [36] SILVA R V，OLIVEIRA J T，SANTOS B L R，et al. Long-
ripheral neuropathy in a rodent model and clinical data‐ chain omega-3 fatty acids supplementation accelerates
base[J]. Toxics，2022，10（11）：669. nerve regeneration and prevents neuropathic pain behavior
[25] CIRRINCIONE A M，PELLEGRINI A D，DOMINY J R， in mice[J]. Front Pharmacol，2017，8：723.
et al. Paclitaxel-induced peripheral neuropathy is caused [37] ZAISS M，UHLIG J，ZAHN M O，et al. Improving
by epidermal ROS and mitochondrial damage through chemotherapy-induced peripheral neuropathy in patients
conserved MMP-13 activation[J]. Sci Rep，2020，10（1）： with breast or colon cancer after end of （neo）adjuvant
3970. therapy：results from the observational study STEFANO
[26] EZAKA M，MARUTANI E，MIYAZAKI Y，et al. Oral ad‐ [J]. Oncol Res Treat，2021，44（11）：613-621.
ministration of glutathione trisulfide increases reactive sul‐ （收稿日期：2023-07-07 修回日期：2023-11-20）
fur levels in dorsal root ganglion and ameliorates （编辑：唐晓莲）
paclitaxel-induced peripheral neuropathy in mice[J]. Anti‐

· 378 · China Pharmacy 2024 Vol. 35 No. 3 中国药房 2024年第35卷第3期